# Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

> **NCT05974059** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Unresectable Gastric Adenocarcinoma

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05974059
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05974059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05974059, "Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05974059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*